Soluble receptor for advanced glycation end products in multiple sclerosis: A                 potential marker of disease severity

Sternberg, Zohara; Weinstock‐Guttman, Bianca; Hojnacki, David; Zamboni, Paolo; Zivadinov, Robert; Chadha, Kailash C.; Lieberman, Alicia; Kazim, Latif; Drake, Allison; Paluch, Rocco A.; Grazioli, Erica; Munschauer, Frederick E.

doi:10.1177/1352458507088105

Cited by 45 publications

(37 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, lower levels of serum sRAGE have been detected in several chronic inflammatory diseases, for example multiple sclerosis (MS), primary Sjogren's syndrome, and rheumatoid arthritis (RA). [29,30] To date, only two studies have investigated the serum sRAGE levels in SLE patients, and they reported conf licting results. [31,32] However, experimental animal models have provided encouraging results about the therapeutic role of sRAGE.…”

mentioning

confidence: 99%

A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus

2013

View full text Add to dashboard Cite

Amaç: Bu çalışmada sistemik lupus eritematöz (SLE) olan hastalarda ileri glikasyon son ürünlerinin çözünür reseptörünün (sRAGE) plazma düzeyleri değerlendirildi ve bu düzeylerin farklı klinik, laboratuvar ve tedavi parametreleri ile olan ilişkisi araştırıldı. Hastalar ve yöntemler:Çalışmaya toplam 120 SLE hastası (111 kadın, 9 erkek) ve yaş ve cinsiyet eşleştirmeli 40 sağlıklı kontrol alındı. Plazma sRAGE düzeyleri, ticari olarak satılan enzim bağlı immünosorbent test (ELISA) kiti kullanılarak ölçüldü. Plazma sRAGE düzeyleri ve SLE'nin klinik ve laboratuvar özellikleri arasındaki muhtemel ilişki de değerlendirildi. Farklı tedavi yöntemlerinin sRAGE plazma düzeyleri üzerindeki etkinliği incelendi. Bulgular: Sağlıklı kontrollere kıyasla, SLE hastalarının plazma sRAGE düzeyleri anlamlı düzeyde daha düşüktü (p=0.003). Cilt döküntüsü veya serozit olan hastaların sRAGE düzeyleri, olmayanlara kıyasla anlamlı düzeyde daha yüksekti (sırasıyla p=0.036 ve p=0.017). Daha uzun süre tedavi edilen SLE hastalarının sRAGE düzeyleri, daha kısa süreli tedavi edilenlerden daha yüksekti (p=0.000). Kortikosteroid ile tedavi edilen ve kombine tedavi edilen hastalar arasında düzey açısından anlamlı bir fark yoktu (p=0.89). sRAGE düzeyleri ve total beyaz kan hücre (WBC) sayımı (r=-0.356; p=0.003), lenfosit (r=0.341; p<0.001) ve nötrofil (r=0.289; p=0.006) arasında anlamlı negatif bir ilişki vardı.Sonuç: Çalışmamızda SLE hastalarında sRAGE plazma düzeylerinin anlamlı derecede azaldığı bulundu. Bu da, sRAGE düzeylerinin hastalığın patogenezinde muhtemel bir rol oynadığını göstermektedir.Anahtar sözcükler: İleri glikasyon son ürünü; reseptör; sistemik lupus eritematöz. Objectives:In this study, we aimed to evaluate the plasma levels of a soluble receptor for advanced glycation end products (sRAGE) in patients with systemic lupus erythematosus (SLE) and to investigate their relationship with different clinical, laboratory, and therapeutic parameters. Patients and methods:A total of 120 patients with SLE (111 females, 9 males) and 40 age-and gender-matched healthy controls were included. The plasma sRAGE levels were measured using a commercially available enzyme-linked immunosorbent assay (ELISA). The possible relationship between plasma sRAGE levels with SLE clinical and laboratory characteristics were also assessed. The effectiveness of different therapeutic modalities on plasma sRAGE levels was analyzed. Results:The SLE patients had significantly lower plasma levels of sRAGE than the healthy controls (p=0.003). The patients with a skin rash or serositis had significantly higher sRAGE levels than those without (p=0.036 and p=0.017, respectively). The SLE patients who were treated over a longer period of time showed higher levels of sRAGE than those treated for shorter periods (p=0.000). No significant difference in levels was found among the patients treated with corticosteroids and those treated with combined therapy (p=0.89). There was a significant negative correlation between the sRAGE level and the total white blood cell (WBC) count (...

show abstract

mentioning

confidence: 99%

A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus

2013

View full text Add to dashboard Cite

show abstract

“…They also detected a relationship between sRAGE and EDSS as well as sRAGE and the rate of clinical relapse in MS patients [18]. The population of patients recruited in the current study was remarkably different from those in the Sternberg et al study, who included 31 RRMS and six secondary progressive (SP) MS patients.…”

Section: Discussionmentioning

confidence: 70%

“…This differs from our homogenized patient population consisting of 50 RRMS patients. More importantly, Sternberg et al enrolled patients who declined to take any Food and Drug Administration approved MS disease-modifying drugs (IFN-β, glatiramer acetate and natalizumab) [18], which could explain the discrepancies between our results and theirs.…”

Section: Discussionmentioning

confidence: 79%

Soluble Receptor for Advanced Glycation End Products (sRAGE) is Up-Regulated in Multiple Sclerosis Patients Treated with Interferon β-1a

Rahimi

Afjeh

Omrani

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system. Considering the role of immune system in its pathogenesis, researchers have focused on evaluation of the expression of immune-related genes or proteins in MS patients. Among proteins whose participation in inflammatory process has been documented is the receptor for advanced glycation end products (RAGE). Methods: In the present study, we compared RAGE transcript levels by means of quantitative real-time PCR as well as the serum level of soluble RAGE (sRAGE) by means of enzyme- linked immunosorbent assay (ELISA) in 50 IFNβ-1a responsive relapsing-remitting MS patients when compared with age and sex-matched healthy subjects. Results: Elevated expression of RAGE as well as higher levels of sRAGE were detected in IFN-β responsive MS patients compared with the controls. A significant inverse correlation between sRAGE plasma concentrations and the expanded disability status scale (EDSS) was also detected in which each unit of increase in sRAGE level resulted in a 0.308 unit decrease in EDSS. Conclusion: Considering the stable clinical state of the MS patients in this study and their response to IFNβ-1a, the elevated levels of sRAGE in patients compared with healthy subjects could be related to the effects of this kind of treatment.

show abstract

“…With respect to sRAGE, akin to other inflammatory neurodegenerative syndromes discussed above, MS patients display lower serum levels of sRAGE relative to control patients and this decreased sRAGE inversely correlates with disease progression [108]. In addition, RAGE ligands are also increased in active MS lesions, as observed by immunohistochemistry.…”

Section: Multiple Sclerosis and Experimental Autoimmune Encephalopathmentioning

confidence: 90%

“…In addition, RAGE ligands are also increased in active MS lesions, as observed by immunohistochemistry. Further, AGER mRNA and RAGE ligand protein concentrations were increased in serum, CSF, and mononuclear cells in both niches during MS [108][109][110][111][112]. Interestingly, patients treated with disease-modifying drugs display a prominent reduction of serum HMGB1 when compared to untreated MS patients, which correlated to a better disease prognosis [111].…”

Section: Multiple Sclerosis and Experimental Autoimmune Encephalopathmentioning

confidence: 99%

The Receptor for Advanced Glycation Endproducts (RAGE) and Mediation of Inflammatory Neurodegeneration

Derk

MacLean

Juranek

et al. 2018

J Alzheimers Dis Parkinsonism

View full text Add to dashboard Cite

Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity

Cited by 45 publications

References 27 publications

A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus

A Soluble Receptor for Advanced Glycation End Product Levels in Patients with Systemic Lupus Erythematosus

Soluble Receptor for Advanced Glycation End Products (sRAGE) is Up-Regulated in Multiple Sclerosis Patients Treated with Interferon β-1a

The Receptor for Advanced Glycation Endproducts (RAGE) and Mediation of Inflammatory Neurodegeneration

Contact Info

Product

Resources

About